↓ Skip to main content

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

Overview of attention for article published in BMC Pharmacology and Toxicology, September 2020
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
Published in
BMC Pharmacology and Toxicology, September 2020
DOI 10.1186/s40360-020-00446-x
Pubmed ID
Authors

Fabian Lang, Lydia Wunderle, Susanne Badura, Eberhard Schleyer, Monika Brüggemann, Hubert Serve, Susanne Schnittger, Nicola Gökbuget, Heike Pfeifer, Sebastian Wagner, Kevin Ashelford, Gesine Bug, Oliver G. Ottmann

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Professor 3 13%
Student > Ph. D. Student 2 8%
Researcher 2 8%
Student > Master 2 8%
Student > Doctoral Student 1 4%
Other 3 13%
Unknown 11 46%
Readers by discipline Count As %
Medicine and Dentistry 9 38%
Immunology and Microbiology 2 8%
Biochemistry, Genetics and Molecular Biology 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Engineering 1 4%
Other 0 0%
Unknown 10 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2023.
All research outputs
#7,922,551
of 23,862,416 outputs
Outputs from BMC Pharmacology and Toxicology
#146
of 460 outputs
Outputs of similar age
#168,066
of 414,648 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#2
of 9 outputs
Altmetric has tracked 23,862,416 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 460 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 414,648 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.